Related Experiment Video
Updated: Aug 11, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials
Seppo Ylä-Herttuala1, Johanna E Markkanen, Tuomas T Rissanen
1Seppo Ylä-Herttuala, Johanna E. Markkanen, and Tuomas T. Rissanen are at the A.I.Virtanen Institute and Department of Medicine, University of Kuopio, Kuopio, Finland. seppo.ylaherttuala@uku.fi
Abstract:
Stimulation of angiogenesis, arteriogenesis, and lymphangiogenesis (i.e., therapeutic vascular growth) is a new concept for the treatment of ischemic cardiovascular diseases. A wealth of information is already available about the mechanisms and mediators of angiogenesis and arteriogenesis, which has led to the first randomized, controlled, phase II/III trials with recombinant growth factors or their genes. Even though end points predefined in the study protocols have been positive in several trials, it is still evident that the trials have not produced any clearly meaningful clinical benefits for the patients. This review addresses same questions and concepts related to the gene therapy-based applications of therapeutic vascular growth.
Related Concept Videos
Gene Therapy
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

